Henletor (torsemide) / Orchid - LARVOL DELTA

SGLT- 2I: "CAN BE A HOPE FOR PERITONEAL DIALYSIS PATIENTS." (ISN-WCN 2026) - "At baseline, his blood pressure was 168/88 mmHg with telmisartan 80 mg/day, amlodipine 10 mg /day, prazosin 10 mg/day, and torsemide 100 mg/day. Other medications were dapagliflozin 10mg/day, linagliptin 5 mg/day, sodium bicarbonate 1000 mg twice daily, insulin, atorvastatin 10mg/day, and aspirin 75 mg/day...There was no hospitalization in this follow-up period.Conclusion As the drug is well tolerated and no adverse effects are noted in this 35-month follow-up, we may hope to use this drug in some dialysis-dependent patients. The findings in this case report need to be confirmed in a large prospective study with a longer follow-up period."

Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Real-world effectiveness and safety of torsemide and spironolactone fixed dose combination in Indian heart failure patients (RESTORE-HF study): a prospective, multicenter, observational study. (PubMed, Ther Adv Cardiovasc Dis) - "The RESTORE-HF study demonstrated that the torsemide-spironolactone FDC may be associated with a mean body weight reduction of 2.41 kg and may be generally well-tolerated in Indian heart failure patients. Furthermore, the FDC may be linked to significant symptomatic improvement over 3 weeks in real-world clinical practice."

Journal • Observational data • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure

BREAKING THE MOLD: A UNIQUE CASE OF LOEFFLER ENDOCARDITIS COMPLICATED BY CARDIOGENIC SHOCK AND ANGIOINASIVE FUSARIUM FUJIKUROI INFECTION (ACC 2026) - "She was initiated on apixaban, prednisone, rituximab and prophylactic trimethoprim-sulfamethoxazole (TMP-SMX). One month later, the patient noted necrotic ulcerations on all four extremities since starting rituximab; lesion biopsies revealed angioinvasive Fusarium fujikuroi, so she was admitted and posaconazole and amphotericin were started...Diuresis with oral torsemide failed due to oliguria, after which she developed cardiogenic shock with a cardiac index of 1.7 L/min/m2 requiring dobutamine and continuous renal replacement therapy (CRRT). With the afterload reduction CRRT provided, she was weaned off dobutamine and CRRT and transitioned to oral furosemide before discharge... Management of LE in patients undergoing immunosuppressive therapy may be complicated by opportunistic infections and medication toxicity. Cardiogenic shock can be caused by the restrictive ventricular physiology of LE."

Clinical • Acute Kidney Injury • Cardiomyopathy • Cardiovascular • Eosinophilia • Eosinophilic Granulomatosis With Polyangiitis • Fibrosis • Heart Failure • Hypereosinophilic Syndrome • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Myocardial Infarction • Rare Diseases • Renal Disease • Vasculitis

LISTENING TO THE HEART: REMOTE IVCT MONITORING WITH HEMOTAG PREVENTS 30-DAY READMISSION IN ACUTE DECOMPENSATED HEART FAILURE (ACC 2026) - "Her physician initiated torsemide 20 mg BID, briefly lowering IVCT... This case illustrates the feasibility and impact of HEMOTAG-guided CTI monitoring in ADHF. Unlike conventional RPM, which relies on weight or blood pressure, HEMOTAG provides direct physiologic assessment of myocardial performance. Physician-supervised interventions based on CTI trends enabled targeted therapy, improved patient stability, and avoided costly hospitalization."

Cardiovascular • Congestive Heart Failure • Heart Failure

EXPLORING INTERVENTIONAL THERAPIES IN RESISTANT HYPERTENSION: DUAL RENAL REVASCULARIZATION AND DENERVATION (ACC 2026) - "Case: A 62 year old woman with a 20-year history of resistant hypertension on five antihypertensive agents (including amlodipine, doxazosin, hydralazine, isosorbide mononitrate, and torsemide) followed with hypertension clinic due to ongoing difficulty controlling blood pressures at home. Our case presents a unique application of dual renal therapy with renal artery stenting and renal sympathetic denervation."

Atherosclerosis • Cardiovascular • Hypertension • Nephrology • Renal Disease • Respiratory Diseases

PULMONARY VASODILATOR THERAPY IN SCHISTOSOMIASIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: DEMONSTRATED BENEFIT AND NEED FOR FURTHER STUDIES. (ACC 2026) - "He improved with intravenous furosemide and was discharged on bosentan, tadalafil, and torsemide. Sch-PAH represents a delayed yet clinically significant sequela of bilharziasis. Our case illustrates the benefit of targeted PAH therapy in this population and emphasizes the need for prospective studies and registries in endemic regions."

Cardiovascular • Hepatology • Infectious Disease • Pulmonary Arterial Hypertension • Respiratory Diseases

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder (clinicaltrials.gov) - P2 | N=24 | Completed | Sponsor: Sarfez Pharmaceuticals, Inc. | Recruiting ➔ Completed | Trial completion date: Jul 2026 ➔ Dec 2025

Trial completion • Trial completion date • Cardiovascular • Congestive Heart Failure • Heart Failure • Overactive Bladder • Urinary Incontinence

NEXT-HF: Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (clinicaltrials.gov) - P4 | N=20 | Completed | Sponsor: Sarfez Pharmaceuticals, Inc. | Recruiting ➔ Completed

Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure

Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone (clinicaltrials.gov) - P3 | N=24 | Completed | Sponsor: Sarfez Pharmaceuticals, Inc. | Recruiting ➔ Completed | Trial completion date: Nov 2026 ➔ Feb 2026 | Trial primary completion date: Jun 2026 ➔ Feb 2026

Trial completion • Trial completion date • Trial primary completion date

In brief: A second subcutaneous furosemide infusor (Lasix ONYU) for heart failure. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects (clinicaltrials.gov) - P3 | N=24 | Completed | Sponsor: Sarfez Pharmaceuticals, Inc. | Recruiting ➔ Completed | Trial completion date: Jun 2026 ➔ Dec 2025

Trial completion • Trial completion date

Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects (clinicaltrials.gov) - P3 | N=24 | Completed | Sponsor: Sarfez Pharmaceuticals, Inc. | Recruiting ➔ Completed | Trial completion date: Jun 2026 ➔ Dec 2025

Trial completion • Trial completion date

Unraveling the Enigma: Diagnostic Complexity in a Case of Idiopathic Membranoproliferative Glomerulonephritis (NKF-SCM 2026) - "At discharge, management involved oral steroids, mycophenolate, torsemide, spironolactone, and chlorthalidone. CONCLUSION Despite improved diagnostic capabilities, idiopathic MPGN remains an enigma. This case highlights the diagnostic complexity of such cases."

Clinical • Chronic Kidney Disease • Fibrosis • Glomerulonephritis • Hematological Malignancies • Hepatology • Immunology • Lupus Nephritis • Lymphoma • Mantle Cell Lymphoma • Nephrology • Pulmonary Disease • Renal Disease

Using Artificial Intelligence to Assess Treatment-Effect Heterogeneity in Pragmatic Cardiovascular Trials: Insights from TRANSFORM-HF. (PubMed, medRxiv) - "Torsemide appeared more beneficial among patients without atrial fibrillation and with lower BNP/NT-proBNP levels, whereas furosemide was favored in those with atrial fibrillation, higher BNP/NT-proBNP concentrations, and prior loop diuretic use. Exploratory analyses demonstrated that applying AI-driven methods to evaluate treatment effect heterogeneity within a pragmatic trial framework can leverage the inherent clinical diversity of pragmatic designs and potentially generate personalized and practice-relevant insights from pragmatic clinical research."

Heterogeneity • Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc. | Trial primary completion date: Jul 2026 ➔ Dec 2025

Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure • Overactive Bladder • Urinary Incontinence

DOCK: Diuretics and Volume Overload in Early CKD (clinicaltrials.gov) - P4 | N=49 | Completed | Sponsor: VA Office of Research and Development | Recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Oct 2025

Trial completion • Trial completion date • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Hypertension • Nephrology • Renal Disease

Effect of Serum Chloride Concentrations on Diuretic Effect in the TRANSFORM-Mechanism Mechanistic Study (KIDNEY WEEK 2025) - "In the TRANSFORM-Mechanism study we found no meaningful pharmacokinetic or pharmacodynamic advantages of torsemide versus furosemide. Increase in serum chloride concentration between visits was also associated with increased eGFR (r=0.317, p=0.013) and increased DE defined as natriuretic response normalized to diuretic dose (r=0.391, p=0.001). Conclusion Regardless of randomized diuretic or prescribed dose, increase in serum chloride concentration between study visits was associated with decreased serum renin concentration and increased eGFR and DE."

Cardiovascular • Congestive Heart Failure • Heart Failure

A Hidden Risk in the Loop: Furosemide-Triggered Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficiency (KIDNEY WEEK 2025) - "Clinicians should consider G6PD deficiency in the differential diagnosis of unexplained hemolysis and remain vigilant regarding the potential oxidative risks of commonly used medications such as furosemide. When loop diuretic therapy is necessary, switching to a chemically related but structurally distinct agent like torsemide may offer a safer alternative in G6PD-deficient patients."

Anemia • Cardiovascular • Chronic Kidney Disease • Diabetes • Dyslipidemia • Hematological Disorders • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • G6PD • HP

Daptomycin-Induced Hyperkalemia in the Absence of Creatinine Kinase Elevation: A Challenging Diagnosis in a Patient with Diabetes and Acute on Chronic CKD (KIDNEY WEEK 2025) - "Ten days prior to admission, her Cr increased from 1.5 to 1.83, and vancomycin was changed to daptomycin 600mg every 48 hours. Other pertinent home medications included cefepime 2g/d, torsemide 20mg/d, lisinopril 5mg/d, and metoprolol succinate 25mg/d...The daptomycin was changed to doxycycline on day 9, and within 48 hours, her K began to downtrend, normalizing at 72 hours while Cr was 3.08...As for this patient, it is important to consider this as her hyperkalemia was challenging to control with prolonged hospitalization prior to daptomycin discontinuation. Timely recognition of daptomycin-induced hyperkalemia should be considered in the differential to improve outcomes."

Clinical • Chronic Kidney Disease • Diabetes • Hematological Disorders • Metabolic Disorders

The Lonely Amyloid's Puzzle: Isolated Renal Apolipoprotein CII Amyloidosis - Familial or Isolated Occurrence? (KIDNEY WEEK 2025) - "Case Description A 63-year-old male with a history of Nephrotic CKD 3b complicated by pulmonary embolism on apixaban presented for proteinuria evaluation...He was started on losartan 25 mg and torsemide 10 mg...While some cases exhibit genetic underpinnings, including amino acid sequence variants and familial occurrence, the novelty of this case lies in the combination of its isolated renal involvement and the absence of protein structural abnormalities or detectable genetic mutations, particularly in the context of a family history of amyloidosis. Management remains primarily supportive."

Amyloidosis • Cardiovascular • Chronic Kidney Disease • Fibrosis • Genetic Disorders • Glomerulonephritis • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Nephrology • Pulmonary Embolism • Renal Disease • Respiratory Diseases

BRASH: A Vicious Cycle (KIDNEY WEEK 2025) - "He was taking metoprolol succinate 25 mg daily, sacubitril-valsartan 24-26 mg twice daily and torsemide 40 mg daily which were held on admission. As per a systematic review, over 50% cases had non-severe hyperkalemia (less than 6.5 mg/dL). With increasing use of beta blockers, ACE/ARBs and MRAs, the incidence of this syndrome will continue to increase and requires more awareness in the community."

Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Hypotension • Renal Disease

Comparing Loop Diuretic Efficacy and Safety in Patients with Acute Myeloid Leukemia and Differentiation Syndrome (ASH 2024) - "Patients were treated with furosemide (n=2,431), bumetanide (n=466), or torsemide (n=206), alongside glucocorticoids and allopurinol. This may be due to bumetanide's higher potency, rapid absorption, and shorter half-life, potentially increasing the risk of electrolyte imbalances and acute kidney injury. Conversely, furosemide may facilitate greater cumulative sodium excretion in patients with chronic renal insufficiency."

Clinical • Acute Kidney Injury • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Heart Failure • Hematological Malignancies • Hypertension • Leukemia • Metabolic Disorders • Nephrology • Oncology • Renal Disease

Comparison of the Efficacy of Torsemide and Furosemide in Managing Ascites Due to Liver Cirrhosis: A Systematic Review and Meta-Analysis (ACG 2025) - "Four randomized controlled trials involving a total of 98 participants, were included in the final analysis. 48 patients were treated with torsemide, while 50 patients were treated with oral furosemide. At the 24-hour mark, diuresis was more pronounced in the torsemide group (TG) compared to the furosemide group (FG), with a mean difference of 0.85 liters (95% CI 0.32-1.38, P=0.002, I2 =82%)."

Retrospective data • Review • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis

NEPHRON: A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (clinicaltrials.gov) - P3 | N=30 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P3 trial • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

SICKLE CELL DISEASE LEADING TO DEBILITATING PULMONARY ARTERIAL HYPERTENSION (CHEST 2025) - "Managing SCD-associated PH primarily focuses on treating the underlying disease with hydroxyurea or chronic blood exchange transfusions, along with anticoagulation for thromboembolism and treatment of left heart failure in those with post-capillary PH...Given clinical volume overload, she was started on torsemide...Although intended to be started on macitentan (an endothelin receptor antagonist), she returned to the hospital with worsening dyspnea before she could get the medication approved...She then became increasingly hypotensive riociguat was uptitrated, requiring initiation of midodrine as well as downtitration of diuresis... SCD-associated PH carries a high mortality risk with a notable lack of evidence on effective therapy options that demonstrate significantly improved outcomes."

Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Hematological Disorders • Hypotension • Pulmonary Arterial Hypertension • Respiratory Diseases • Sickle Cell Disease